Stocks of Janux Therapeutics Inc (NASDAQ:JANX) traded higher last session on Wall Street, up 11.65% to $66.83.
JANX stock price is now 33.04% away from the 50-day moving average and 47.34% away from the 200-day moving average. The market capitalization of the company currently stands at $3.51B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $63 to $70, H.C. Wainwright maintained Buy rating for Janux Therapeutics Inc (NASDAQ: JANX). On December 03, 2024, BTIG Research reiterated its ‘Buy’ rating on the stock by increasing its target price from $82 to quote $100, while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, Campbell David Alan, President and CEO sold 15,000 shares of the company’s stock on Dec 03 ’24. The stock was sold for $1,005,000 at an average price of $67.00. Upon completion of the transaction, the President and CEO now directly owns 242,054 shares in the company, valued at $16.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 25 ’24, President and CEO Campbell David Alan sold 25,000 shares of the business’s stock. A total of $1,289,879 was realized by selling the stock at an average price of $51.60. This leaves the insider owning 257,054 shares of the company worth $17.18 million. A total of 18.70% of the company’s stock is owned by insiders.
During the past 12 months, Janux Therapeutics Inc has had a low of $7.79 and a high of $71.25. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 38.80, and a quick ratio of 38.80. The fifty day moving average price for JANX is $49.8732 and a two-hundred day moving average price translates $45.076324 for the stock.
The latest earnings results from Janux Therapeutics Inc (NASDAQ: JANX) was released for 2024-09-30. The net profit margin was -463.91% and return on equity was -12.05% for JANX. The company reported revenue of $0.44 million for the quarter, compared to $2.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -82.56 percent.
